Tejnaksh Healthcare Intrinsic Value
Tejnaksh Healthcare (TEJNAKSH) median intrinsic value is ₹20.32 from 8 valuation models (range ₹4–₹36), vs current price ₹14.25 — +42.6% upside (Trading Below Calculated Value), margin of safety 29.9%. Read TEJNAKSH ex-dividend dates for the complete payout history and dividend yield track record.
TEJNAKSH Valuation Methods Summary — DCF, Graham Number & P/E
Tejnaksh Healthcare intrinsic value across 8 models vs current price ₹14.25 — upside/downside and value range per method. For current market price and key ratios, visit Tejnaksh Healthcare share price today.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹8.16 | ₹6.53 - ₹9.79 | -42.7% | EPS: ₹0.68, Sector P/E: 12x |
| Book Value Method | asset | ₹27.00 | ₹24.30 - ₹29.70 | +89.5% | Book Value/Share: ₹27.00, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹9.60 | ₹8.64 - ₹10.56 | -32.6% | Revenue/Share: ₹12.00, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹24.00 | ₹21.60 - ₹26.40 | +68.4% | EBITDA: ₹4.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹35.62 | ₹28.50 - ₹42.74 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹4.35 | ₹3.91 - ₹4.79 | -69.5% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹5.60 | ₹5.04 - ₹6.16 | -60.7% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| Graham Defensive Method | conservative | ₹20.32 | ₹18.29 - ₹22.35 | +42.6% | EPS: ₹0.68, BVPS: ₹27.00 |
TEJNAKSH Intrinsic Value vs Market Price — All Valuation Models
Tejnaksh Healthcare fair value range ₹4–₹36 vs current market price ₹14.25 across 8 valuation models. Analyse Tejnaksh Healthcare ownership pattern to track promoter, FII and institutional holdings.
TEJNAKSH Intrinsic Value Analysis — Undervalued or Overvalued?
Tejnaksh Healthcare median intrinsic value ₹20.32, current price ₹14.25 — Trading Below Calculated Value by 42.6%, margin of safety 29.9%.
What is the intrinsic value of TEJNAKSH?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Tejnaksh Healthcare (TEJNAKSH) is ₹20.32 (median value). With the current market price of ₹14.25, this represents a +42.6% variance from our estimated fair value.
The valuation range spans from ₹4.35 to ₹35.62, indicating ₹4.35 - ₹35.62.
Is TEJNAKSH undervalued or overvalued?
Based on our multi-method analysis, Tejnaksh Healthcare (TEJNAKSH) appears to be trading below calculated value by approximately 42.6%.
TEJNAKSH Financial Health — Key Ratios vs Industry Benchmarks
Tejnaksh Healthcare financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 2.50 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Operating Margin | 28.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.40x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
TEJNAKSH Cash Flow Quality — Operating & Free Cash Flow
Tejnaksh Healthcare operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹4 Cr | ₹4 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹2 Cr | ₹2 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹9 Cr | ₹4 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |